Pharma Faces More Probes On Generic Price Hikes in UK
As Concordia finds itself in the dock again, this time over its pricing of the essential thyroid treatment liothyronine, the UK's Competition and Markets Authority has recently opened four new investigations into "suspected abuse of dominance" concerning generics.
You may also be interested in...
The UK's competition authority is keen to expose supposed pay-for-delay deals made by pharmaceutical firms, and is warning drug suppliers to think twice before attempting agreements that slow the entry of generic products onto the UK market.
The UK competition authority has fined Pfizer and Flynn Pharma a total of £90m for charging “excessive and unfair” prices for phenytoin sodium capsules; Pfizer has said it will appeal. With an earlier CMA decision to impose a hefty fine on GlaxoSmithKline for its part in a pay-for-delay deal, companies should pay careful consideration to any competition issues raised by their pricing strategies for marketed drugs.
Competition and Markets authority levies fines on GSK and two generics firms for agreement on paroxetine.